Literature DB >> 20442654

Evolution of induced pluripotent stem cell technology.

Hongyan Zhou1, Sheng Ding.   

Abstract

PURPOSE OF REVIEW: Induced pluripotent stem cell (iPSC) technology, which uses defined transcription factors to reprogram somatic cells to become pluripotent cells, offers a significant technical simplicity and enables generation of patient-specific pluripotent stem cells with reduced ethical concerns. This review will focus on recent progresses in understanding of iPSCs and improved methods of generating iPSCs. RECENT
FINDINGS: Whereas iPSCs generated from a variety of cell sources were found to be nearly identical functionally to embryonic stem cells, some differences were also identified and remain to be characterized. Meanwhile, new methods of generating iPSCs with minimal or no exogenous genetic modifications to cells have advanced rapidly.
SUMMARY: iPSC technology provides unprecedented opportunities in biomedical research and regenerative medicine. However, there remain a great deal to learn about iPSC safety, the reprogramming mechanisms, and better ways to direct a specific reprogramming process. The iPSC field will flourish on its mechanistic studies, iPSC-based disease modeling, and identification of new small molecules that modulate reprogramming.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20442654     DOI: 10.1097/MOH.0b013e328339f2ee

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  16 in total

1.  Grand challenge commentary: Synthetic immunology to engineer human immunity.

Authors:  David A Spiegel
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

2.  Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix.

Authors:  Elias Uhlin; Ana Marin Navarro; Harriet Rönnholm; Kelly Day; Malin Kele; Anna Falk
Journal:  J Vis Exp       Date:  2017-07-07       Impact factor: 1.355

Review 3.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

Review 4.  The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine.

Authors:  N Forraz; C P McGuckin
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

Review 5.  The evolving biology of small molecules: controlling cell fate and identity.

Authors:  Jem A Efe; Sheng Ding
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-08-12       Impact factor: 6.237

Review 6.  Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives.

Authors:  Alexander E Berezin
Journal:  World J Diabetes       Date:  2014-12-15

7.  Generation of induced pluripotent stem cells from mouse cancer cells.

Authors:  Frances Ka-Yin Lin; Yiu-Loon Chui
Journal:  Cancer Biother Radiopharm       Date:  2012-08-14       Impact factor: 3.099

Review 8.  Cell sources for bone regeneration: the good, the bad, and the ugly (but promising).

Authors:  Pamela Gehron Robey
Journal:  Tissue Eng Part B Rev       Date:  2011-07-28       Impact factor: 6.389

Review 9.  Stem cell technology for the study and treatment of motor neuron diseases.

Authors:  J Simon Lunn; Stacey A Sakowski; Thais Federici; Jonathan D Glass; Nicholas M Boulis; Eva L Feldman
Journal:  Regen Med       Date:  2011-03       Impact factor: 3.806

10.  Differentiation of mesenchymal stem cells derived from pancreatic islets and bone marrow into islet-like cell phenotype.

Authors:  Cristina Zanini; Stefania Bruno; Giorgia Mandili; Denisa Baci; Francesco Cerutti; Giovanna Cenacchi; Leo Izzi; Giovanni Camussi; Marco Forni
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.